GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Ending Cash Position

CMPX (Compass Therapeutics) Ending Cash Position : $43.48 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Therapeutics Ending Cash Position?

Compass Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was $43.48 Mil.

Compass Therapeutics's quarterly Ending Cash Position increased from Jun. 2024 ($19.40 Mil) to Sep. 2024 ($37.37 Mil) and increased from Sep. 2024 ($37.37 Mil) to Dec. 2024 ($43.48 Mil).

Compass Therapeutics's annual Ending Cash Position declined from Dec. 2022 ($34.95 Mil) to Dec. 2023 ($24.23 Mil) but then increased from Dec. 2023 ($24.23 Mil) to Dec. 2024 ($43.48 Mil).

Compass Therapeutics Ending Cash Position Historical Data

The historical data trend for Compass Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Therapeutics Ending Cash Position Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial 47.34 144.51 34.95 24.23 43.48

Compass Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.23 23.67 19.40 37.37 43.48

Compass Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Compass Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=24.228+19.255
=43.48

Compass Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=37.369+6.114
=43.48

Compass Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Compass Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Ending Cash Position
Comparable Companies
AURA MNPR TSVT ABEO LXRX PVLA SLDB ITOS TERN CYDY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 601, Boston, MA, USA, 02135
Website
https://www.compasstherapeutics.com
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard S Lindahl director NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Thomas J. Schuetz director, officer: Chief Executive Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
David M Wurzer director C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Vered Bisker-leib officer: Chief Operating Officer C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Philip Ferneau director 10 ALLEN STREET, HANOVER NH 03755
Orbimed Capital Gp V Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled officer: Chief Scientific Officer COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016